0001562180-21-000931.txt : 20210205 0001562180-21-000931.hdr.sgml : 20210205 20210205162127 ACCESSION NUMBER: 0001562180-21-000931 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210203 FILED AS OF DATE: 20210205 DATE AS OF CHANGE: 20210205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Meyers Michael L. CENTRAL INDEX KEY: 0001664204 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37708 FILM NUMBER: 21595685 MAIL ADDRESS: STREET 1: C/O SYNDAX PHARMACEUTICALS, INC. STREET 2: 400 TOTTEN POND ROAD, SUITE 110 CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Syndax Pharmaceuticals Inc CENTRAL INDEX KEY: 0001395937 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320162505 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 GATEHOUSE DRIVE STREET 2: BUILDING D, FLOOR 3 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-419-1400 MAIL ADDRESS: STREET 1: 35 GATEHOUSE DRIVE STREET 2: BUILDING D, FLOOR 3 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2021-02-03 false 0001395937 Syndax Pharmaceuticals Inc SNDX 0001664204 Meyers Michael L. C/O SYNDAX PHARMACEUTICALS, INC. 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3 WALTHAM MA 02451 false true false false SVP, Chief Medical Officer Common Stock 2020-07-31 4 J false 2665.00 7.97 A 13395.00 D Common Stock 2021-01-31 4 J false 1771.00 12.00 A 15166.00 D Stock Option (Right to Buy) 21.36 2021-02-03 4 A false 80000.00 0.00 A 2031-02-03 Common Stock 80000.00 80000.00 D The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 2,665 shares by the Reporting Person on 07/31/2020 pursuant to the Issuer's Employee Stock Purchase Plan. The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,771 shares by the Reporting Person on 01/31/2021 pursuant to the Issuer's Employee Stock Purchase Plan. 1/48th of the shares subject to the option shall vest monthly over a four-year period. /s/ Michael A. Metzger, Attorney-in-Fact 2021-02-05